Non-Idiopathic Scoliosis Treated With Tranexamic Acid
Non-Idiopathic Scoliosis Treated With Tranexamic Acid
Investigation of tranexamic acid (TXA) for reducing perioperative blood loss and transfusion
 requirement in pediatric patients with secondary scoliosis undergoing posterior spinal
 fusion.
To investigate whether tranexamic acid (TXA) reduces perioperative blood loss and transfusion
 requirement in pediatric patients with secondary scoliosis undergoing posterior spinal
 fusion.In addition determination of the optimal TXA dosing for perioperative reduction of
 blood loss and transfusion requirement as well as to evaluate use of thromboelastography
 (TEG) as a measure of coagulation and fibrinolysis in pediatric patients with secondary
 scoliosis undergoing posterior spinal fusion (this may help guide blood product therapy).

 The investigation will determine the effects of TXA on the TEG profile and whether
 plasminogen activator inhibitor-1 (PAI-1) level affects bleeding and transfusion requirement
 during scoliosis surgery. Finally to investigate whether PAI-1 level affects bleeding in
 response to TXA during scoliosis surgery.
Inclusion Criteria:

 1. Children with secondary scoliosis undergoing posterior spinal fusion

 Exclusion Criteria:

 1. Known bleeding disorder as this may increase the risk of bleeding

 2. Current antifibrinolytic therapy as these patients may bleed less

 3. Patient or family history of thromboembolic disease as there may be potential risk of
 thrombosis

 4. Use of NSAIDS within 5 days of surgery as this may increase the risk of bleeding

 5. Known allergy to TXA

 6. History of renal insufficiency as TXA is renally excreted

 7. Colour vision disturbance